Delivery Order SPE2DR25D1205-SPE2DR26F1AY0
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Zoladex 10.8 mg implant syringes with a ceiling value of $5,878.86. This firm fixed price delivery order, with an ultimate completion date of December 31, 2025, represents a non-competitive set-aside transaction under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The contract is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 22, 2025, for the supply of Zoladex 10.8 mg implant syringes with a ceiling value of $23,515.44. This firm fixed-price delivery order, set to be completed by January 14, 2026, will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award was made on a non-set-aside, competitive basis, reflecting AmerisourceBergen's capability to meet federal procurement standards through...
- The Defense Logistics Agency awarded a $6,055.80 delivery order to AmerisourceBergen Drug Corp on January 7, 2026, for the supply of Zoladex 10.8 mg implant syringes, with final delivery required by January 29, 2026. This contract utilizes a firm fixed-price structure with no set-aside designation, reflecting a competitive award to the prime contractor. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $6,055.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 12, 2026, for the supply of Zoladex 10.8 mg implant syringes, with an ultimate completion date of February 3, 2026. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location. The company...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Zoladex 10.8 mg implant syringes under a firm fixed-price contract with a ceiling value of $7,564.32. The contract is scheduled for ultimate completion by August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and...
- The Defense Logistics Agency awarded a $2,018.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zoladex 10.8 mg implant syringes, with an ultimate completion date of February 10, 2026. This non-set-aside delivery order was awarded on January 20, 2026, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., is a major pharmaceutical distributor that serves as a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a contract ceiling value of $37,190. This is a firm fixed-price delivery order with an ultimate completion date of August 11, 2025, and represents a non-set-aside competitive award. The delivery will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a ceiling value of $3,719.00 and ultimate completion date of October 1, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $17,636.58 to AmerisourceBergen Drug Corp for the supply of Zoladex 10.8 mg implant syringes. This competitively awarded, firm fixed-price contract was executed on December 3, 2025, with an ultimate completion date of December 24, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $5,578.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Zoladex 10.8 mg implant syringes, with completion scheduled for October 14, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor,...
- SPE2DR25D1205Indefinite Delivery Contract
- SPE2DR25D1205-SPE2DR26F1AY0Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 29, 2026, for the supply of Zoladex 10.8 mg implant syringes, valued at $2,018.60. This firm fixed-price delivery order, which carries an ultimate completion date of February 20, 2026, represents a non-competitive award under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal military and veteran healthcare systems, with performance of this order taking place at the company's corporate office location in Conshohocken, PA. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s comprehensive $999.99 billion Indefinite Delivery Contract with DLA Troop Support Medical, which extends through December 2031 and enables global pharmaceutical support for military healthcare programs. The Zoladex product delivery supports the Defense Health Agency and broader military medical treatment facilities requiring specialty pharmaceutical commodities. As a non-set-aside award, this contract reflects the company's competitive standing to fulfill essential pharmaceutical supply requirements for federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 1/28/26 |